SOURCE: MBio Diagnostics, Inc.

MBio Diagnostics, Inc.

January 03, 2013 17:00 ET

MBio Diagnostics, Inc. Will Present at Biotech Showcase in San Francisco, Monday January 7, 2013

BOULDER, CO--(Marketwire - Jan 3, 2013) - MBio Diagnostics, Inc., a diagnostics company focused on enabling better healthcare decisions through immediate multi-disease diagnostics, today announced that Michael J. Lochhead, Ph.D., Vice President of MBio Diagnostics, will present a company overview at the Biotech Showcase, on Monday, January 7 at 2:30 p.m. PST at the Parc 55 Hotel in San Francisco, CA. The presentation will focus on MBio's near-term plans to commercialize the first in a pipeline of diagnostic products on a single platform developed to deliver comprehensive testing of multiple diseases from a single sample.

About MBio:

MBio Diagnostics, Inc. (www.mbiodx.com) is a privately held clinical diagnostics and life sciences technology company based in Boulder, CO. MBio is developing a suite of simple, multiplexed diagnostic tests using its proprietary LightDeck™ technology. Initial product development focuses on high impact infectious diseases, including HIV, hepatitis, and influenza. The company's product development is aimed at decentralized testing, from the clinic to the home.

Contact Information

  • For more information visit MBio at www.mbiodx.com or contact:

    Michael Seely
    MBio Diagnostics, Inc.
    Phone: 303-952-2830
    Fax: 303-951-1529
    E-mail: Email Contact